Antisense Oligonucleotides and RNA Interference - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 329

7. Lilly http://

clinicaltrials.gov

LY2181308 Phase I/II Survivin Cancer Intravenous

infusion

LOE gapmers

http://
clinicaltrials.gov

LY2275796 Phase I eIF-4E Cancer Intravenous

infusion

LOE

8. Topigen

Pharmaceuticals

http:// www
.topigen.com

ASM8 Phase I/II CCR3 and

common beta
chain of IL-3/5
and GM-CSF
receptors

Asthma Inhalation Proprietary

oligonucleotide
technology

9. Aegera

Therapeutics

http:// www
.aegera.com

AEG35156 Phase IIB XIAP mRNA Chemosensitization

of cancer cells

Intravenous
infusion

MBO

10. Santaris Pharma http://

clinicaltrials.gov

SPC3647 Phase I miRNA 122 Hepatitis C Not available LNA AS ODN

11. VasGene

Therapeutics

http:// www
.vasgene.com

Veglin Phase I/II VEGF Cancer Intravenous

infusion

Phosphothiorate
AS ODN

12. Antisense Pharma http:// www

.antisense-
pharma.com

AP 12009 Phase III TGF-2 Cancer Intratumorally Phosphothiorate

AS ODN

13. MethylGene/MGI

Pharma/British
Biotech

http://
clinicaltrials.gov

MG 98 Phase II (Not

in trials)

DNA
methyltransferase

Cancer Not available MBO

14. Eleos, Inc. Aezea®

(Cenersen)

Phase II p53 Acute myelogenous

leukemia

Intravenous
infusion

Phosphothiorate
AS ODN

15. Epigenesis/Genta EPI-2010

(RASON)

Phase II (Not
in trials)

Adenosine A1
receptor

Asthma Not available Phosphothiorate

AS ODN

16. Idera

Pharmaceuticals/
Merck

IMO-2055 Phase Ib TLR9 agonist Non-small cell

lung cancer and
colorectal cancer

Subcutaneous Immunomodulatory

oligonucleotide